Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Early Chronic Phase CML
NCT00254423Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2005
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in chronic myelogenous leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2005; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00254423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254423.